The incidence of renal-related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active-and placebo-controlled trials (N = 5598) and in a 104-week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non-canagliflozin groups. In the study vs glimepiride, canagliflozin was associated with an initial acute decrease in estimated glomerular filtration rate (eGFR) that attenuated over time, while eGFR declined progressively over 104 weeks with glimepiride. The incidence of renal-related AEs with canagliflozin was generally stable over time, while the incidence with glimepiride increased over 104 weeks. In the present analysis, based on postmarketing reports from the US Food and Drug Administration Adverse Event Reporting System, a potential signal was identified for acute kidney injury with all approved sodium glucose co-transporter 2 (SGLT2) inhibitors (ie, canagliflozin, dapagliflozin and empagliflozin). The early onset of acute kidney injury events with SGLT2 inhibitors in postmarketing reports probably reflects the acute changes in eGFR attibutable to the known renal haemodynamic effects of SGLT2 inhibition. The US Food and Drug Administration (FDA) recently revised the labels of the SGLT2 inhibitors, canagliflozin, dapagliflozin and empagliflozin to strengthen existing renal safety warnings by including information on an increased risk of acute kidney injury and recommendations to minimize this risk.
| INTRODUCTION
Sodium glucose co-transporter 2 (SGLT2) inhibitors are a novel class of drugs for the treatment of hyperglycaemia in adults with type 2 diabetes mellitus (T2DM).
1 SGLT2 is responsible for glucose reabsorption in the proximal tubule of the kidney. 1 SGLT2 inhibition lowers the renal threshold for glucose in patients with T2DM, thereby increasing urinary glucose excretion, resulting in lowered blood glucose, a mild osmotic diuresis and a net caloric loss. 1 In clinical studies, acute, reversible declines in estimated glomerular filtration rate (eGFR) with commensurate increases in serum creatinine have been observed with SGLT2 inhibitors, consistent with the haemodynamic effect of these agents. 2 Antihypertensive agents that target the renin-angiotensin-aldosterone system (RAAS; ie, angiotensinconverting enzyme [ACE] inhibitors and angiotensin II receptor blockers) are also associated with acute, reversible declines in renal function in patients with T2DM early in treatment, as measured by decreased eGFR and increased serum creatinine; these changes are the result of reduced intraglomerular pressure via the haemodynamic effect of RAAS inhibition. 3 Treatment with these agents, however, is also associated with reduced proteinuria and reduced risk of endstage renal disease. The incidence of renal-related AEs was assessed in a pooled population that included data from patients with T2DM (N = 5598) enrolled in 7 placebo-and active-controlled studies who were randomized to receive canagliflozin 100 or 300 mg or non-canagliflozin (ie, placebo, sitagliptin or glimepiride) once daily as monotherapy or in combination with various background antihyperglycaemic agents for up to 104 weeks (Table S2 , Supporting Information). 
| Ethics approval and consent to participate
All studies included in this analysis were conducted in accordance with the ethical principles that comply with the Declaration of Helsinki and are consistent with good clinical practices and applicable regulatory requirements. Study protocols and amendments were approved by institutional review boards/ethics committees at the participating institutions. All patients provided written informed consent prior to participation.
| RESULTS

| Clinical trial data
In the pooled population, the incidence of renal-related AEs was low and similar among groups (2.6%, 2.8% and 2.8% with canagliflozin 100 and 300 mg and non-canagliflozin, respectively). The most common reported terms were blood creatinine level increased, GFR decreased, and renal impairment. In the 104-week study vs glimepiride, decreases in eGFR were observed at week 4 of canagliflozin treatment that attenuated over time; eGFR declined progressively with glimepiride ( Figure 1A ). Figure 1A . Few patients discontinued as a result of renal-related AEs over 104 weeks: 1 patient with canagliflozin 100 mg (blood creatinine increased), 7 patients with canagliflozin 300 mg (n = 1, blood creatinine increased; n = 4, GFR decreased; n = 2, renal failure) and 1 patient with glimepiride (GFR decreased). 
| Postmarketing data
| DISCUSSION
The recent FDA revision to the labels for the SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin suggests an increased risk of acute kidney injury with these therapies based on spontaneous postmarketing reporting to the FDA. similar renoprotective effect for patients with T2DM. 1, 14 In a post hoc analysis of renal outcomes in the EMPA-REG OUTCOME trial, empagliflozin was associated with a slower progression of kidney disease and lower rates of clinically relevant renal events compared with placebo in patients with T2DM and established cardiovascular disease. 16 Consistently, in a post hoc analysis of the 104-week add-on to metformin vs glimepiride study, canagliflozin was associated with a lower rate of eGFR decline vs glimepiride, further suggesting that canagliflozin may slow the progression of kidney function decline in patients with T2DM. 17 Evaluating patients' volume status before initiating SGLT2 inhibitors and maintaining adequate fluid intake during treatment may minimize the risk of acute kidney injury.
Further research is needed to better understand the incidence of acute kidney injury with SGLT2 inhibitors and the overall renal 
